168 related articles for article (PubMed ID: 15003313)
1. Diphtheria toxin fused to variant interleukin-3 provides enhanced binding to the interleukin-3 receptor and more potent leukemia cell cytotoxicity.
Liu TF; Urieto JO; Moore JE; Miller MS; Lowe AC; Thorburn A; Frankel AE
Exp Hematol; 2004 Mar; 32(3):277-81. PubMed ID: 15003313
[TBL] [Abstract][Full Text] [Related]
2. Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors.
Hogge DE; Yalcintepe L; Wong SH; Gerhard B; Frankel AE
Clin Cancer Res; 2006 Feb; 12(4):1284-91. PubMed ID: 16489085
[TBL] [Abstract][Full Text] [Related]
3. Diphtheria toxin fused to variant human interleukin-3 induces cytotoxicity of blasts from patients with acute myeloid leukemia according to the level of interleukin-3 receptor expression.
Testa U; Riccioni R; Biffoni M; Diverio D; Lo-Coco F; Foà R; Peschle C; Frankel AE
Blood; 2005 Oct; 106(7):2527-9. PubMed ID: 15928038
[TBL] [Abstract][Full Text] [Related]
4. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors.
Feuring-Buske M; Frankel AE; Alexander RL; Gerhard B; Hogge DE
Cancer Res; 2002 Mar; 62(6):1730-6. PubMed ID: 11912147
[TBL] [Abstract][Full Text] [Related]
5. Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials.
Urieto JO; Liu T; Black JH; Cohen KA; Hall PD; Willingham MC; Pennell LK; Hogge DE; Kreitman RJ; Frankel AE
Protein Expr Purif; 2004 Jan; 33(1):123-33. PubMed ID: 14680969
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia.
Frankel AE; Powell BL; Hall PD; Case LD; Kreitman RJ
Clin Cancer Res; 2002 May; 8(5):1004-13. PubMed ID: 12006512
[TBL] [Abstract][Full Text] [Related]
7. High affinity interleukin-3 receptor expression on blasts from patients with acute myelogenous leukemia correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein.
Alexander RL; Ramage J; Kucera GL; Caligiuri MA; Frankel AE
Leuk Res; 2001 Oct; 25(10):875-81. PubMed ID: 11532521
[TBL] [Abstract][Full Text] [Related]
8. Characterization of variant diphtheria toxin-interleukin-3 fusion protein, DTIL3K116W, for phase I clinical trials.
Su Y; Li SY; Ghosh S; Ortiz J; Hogge DE; Frankel AE
Biologicals; 2010 Jan; 38(1):144-9. PubMed ID: 19783458
[TBL] [Abstract][Full Text] [Related]
9. Interleukin 7 (IL-7) receptor-specific cell killing by DAB389 IL-7: a novel agent for the elimination of IL-7 receptor positive cells.
Sweeney EB; Foss FM; Murphy JR; vanderSpek JC
Bioconjug Chem; 1998; 9(2):201-7. PubMed ID: 9548535
[TBL] [Abstract][Full Text] [Related]
10. Diphtheria toxin-interleukin-3 fusion protein (DT(388)IL3) prolongs disease-free survival of leukemic immunocompromised mice.
Black JH; McCubrey JA; Willingham MC; Ramage J; Hogge DE; Frankel AE
Leukemia; 2003 Jan; 17(1):155-9. PubMed ID: 12529673
[TBL] [Abstract][Full Text] [Related]
11. In vitro interleukin-3 binding to leukemia cells predicts cytotoxicity of a diphtheria toxin/IL-3 fusion protein.
Alexander RL; Kucera GL; Klein B; Frankel AE
Bioconjug Chem; 2000; 11(4):564-8. PubMed ID: 10898579
[TBL] [Abstract][Full Text] [Related]
12. Acute-myeloid-leukemia-targeted toxins kill tumor cells by cell-type-specific mechanisms and synergize with TRAIL to allow manipulation of the extent and mechanism of tumor cell death.
Horita H; Frankel AE; Thorburn A
Leukemia; 2008 Mar; 22(3):652-5. PubMed ID: 17882279
[No Abstract] [Full Text] [Related]
13. Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias.
Frankel AE; McCubrey JA; Miller MS; Delatte S; Ramage J; Kiser M; Kucera GL; Alexander RL; Beran M; Tagge EP; Kreitman RJ; Hogge DE
Leukemia; 2000 Apr; 14(4):576-85. PubMed ID: 10764142
[TBL] [Abstract][Full Text] [Related]
14. High-level expression and purification of the recombinant diphtheria fusion toxin DTGM for PHASE I clinical trials.
Frankel AE; Ramage J; Latimer A; Feely T; Delatte S; Hall P; Tagge E; Kreitman R; Willingham M
Protein Expr Purif; 1999 Jun; 16(1):190-201. PubMed ID: 10336877
[TBL] [Abstract][Full Text] [Related]
15. Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice.
Yalcintepe L; Frankel AE; Hogge DE
Blood; 2006 Nov; 108(10):3530-7. PubMed ID: 16882709
[TBL] [Abstract][Full Text] [Related]
16. Diphtheria toxin-epidermal growth factor fusion protein and Pseudomonas exotoxin-interleukin 13 fusion protein exert synergistic toxicity against human glioblastoma multiforme cells.
Liu TF; Willingham MC; Tatter SB; Cohen KA; Lowe AC; Thorburn A; Frankel AE
Bioconjug Chem; 2003; 14(6):1107-14. PubMed ID: 14624623
[TBL] [Abstract][Full Text] [Related]
17. Production of recombinant DTctGMCSF fusion toxin in a baculovirus expression vector system for biotherapy of GMCSF-receptor positive hematologic malignancies.
Williams MD; Rostovtsev A; Narla RK; Uckun FM
Protein Expr Purif; 1998 Jul; 13(2):210-21. PubMed ID: 9675065
[TBL] [Abstract][Full Text] [Related]
18. Analysis of antitumor activity of an interleukin-13 (IL-13) receptor-targeted cytotoxin composed of IL-13 antagonist and Pseudomonas exotoxin.
Kioi M; Kawakami K; Puri RK
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6231-8. PubMed ID: 15448012
[TBL] [Abstract][Full Text] [Related]
19. Cell-specific modulation of drug resistance in acute myeloid leukemic blasts by diphtheria fusion toxin, DT388-GMCSF.
Frankel AE; Hall PD; McLain C; Safa AR; Tagge EP; Kreitman RJ
Bioconjug Chem; 1998; 9(4):490-6. PubMed ID: 9667951
[TBL] [Abstract][Full Text] [Related]
20. Interleukin 2 receptor-targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin-related interleukin 2 fusion protein into cells.
Waters CA; Schimke PA; Snider CE; Itoh K; Smith KA; Nichols JC; Strom TB; Murphy JR
Eur J Immunol; 1990 Apr; 20(4):785-91. PubMed ID: 2140788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
